Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
SAN DIEGO, Jan. 12, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock (including 750,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares) at a price to the public of $20.00 per share, for total gross proceeds of $115 million, before deducting the underwriting discounts and commissions and other offering expenses. All of the common stock was sold by Otonomy.
BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as joint book-running managers for the offering. Sanford C. Bernstein and SunTrust Robinson Humphrey acted as co-managers.
A shelf registration statement (File No. 333-206752) was previously filed with the Securities and Exchange Commission (SEC) on September 3, 2015 and became effective on September 14, 2015. The final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting one of the following: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or by email at [email protected]; Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department; or Piper Jaffray & Co., 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, or by telephone at 800-747-3924, or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
Contacts: Media Inquiries Canale Communications Heidi Chokeir, Ph.D. Senior Vice President 619.849.5377 [email protected] Investor Inquiries Westwicke Partners Robert H. Uhl Managing Director 858.356.5932 [email protected]
